2024 · ECLINICALMEDICINE

Risk of recurrence after discontinuing anticoagulation in patients with COVID-19associated venous thromboembolism: a prospective multicentre cohort study

Jara-Palomares, Luis, Bikdeli, Behnood, Jimenez, David, Muriel, Alfonso, Demelo-Rodriguez, Pablo, Moustafa, Fares, Villalobos, Aurora, Lopez-Miguel, Patricia, Lopez-Jimenez, Luciano, Otalora, Sonia, Peris, Maria Luisa, Amado, Cristina, Chopard, Romain, Rivera-Civico, Francisco, Monreal, Manuel, RIETE Investigators

Journal
ECLINICALMEDICINE
Année
2024
Volume
73
Article
102659
Mois
JUL
DOI
10.1016/j.eclinm.2024.102659

Abstract

Background The clinical relevance of recurrent venous thromboembolism (VTE) after discontinuing anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence rates and mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19associated VTE. Methods A prospective, multicenter, non-interventional study was conducted between March 25, 2020, and July 26, 2023, including patients who had discontinued anticoagulation after at least 3 months of therapy. All patients from the registry were analyzed during the study period to verify inclusion criteria. Patients with super fi cial vein thrombosis, those who did not receive at least 3 months of anticoagulant therapy, and those who were followed for less than 15 days after discontinuing anticoagulation were excluded. Outcomes were: 1) Incidence rates of symptomatic VTE recurrences, and 2) fatal PE. The rate of VTE recurrences was de fi ned as the number of patients with recurrent VTE divided by the patient-years at risk of recurrent VTE during the period when anticoagulation was discontinued. Findings Among 1106 patients with COVID-19-associated VTE (age 62.3 +/- 14.4 years; 62.9% male) followed-up for 12.5 months (p25-75, 6.3 - 20.1) after discontinuing anticoagulation, there were 38 VTE recurrences (3.5%, 95% con fi dence interval [CI]: 2.5 - 4.7%), with a rate of 3.1 per 100 patient -years (95% CI: 2.2 - 4.2). No patient died of recurrent PE (0%, 95% CI: 0 - 7.6%). Subgroup analyses showed that patients with diagnosis in 2021 - 2022 (vs. 2020) (Hazard ratio [HR] 2.86; 95% CI 1.45 - 5.68) or those with isolated deep vein thrombosis (vs. pulmonary embolism) (HR 2.31; 95% CI 1.19 - 4.49) had signi fi cantly higher rates of VTE recurrences. Interpretation In patients with COVID-19-associated VTE who discontinued anticoagulation after at least 3 months of treatment, the incidence rate of recurrent VTE and the case -fatality rate was low. Therefore, it conceivable that longterm anticoagulation may not be required for many patients with COVID-19-associated VTE, although further research is needed to con fi rm these fi ndings.

Lire l'article complet